Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Hesperidin on Metabolic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03734874
Recruitment Status : Recruiting
First Posted : November 8, 2018
Last Update Posted : November 8, 2018
Sponsor:
Information provided by (Responsible Party):
Dr Azita Hekmatdoost, National Nutrition and Food Technology Institute

Brief Summary:
To study the effects of Hesperidin supplement in patients with metabolic syndrome, 50 patients will be randomly allocated to control group or 2 capsules Hesperidin for 12 weeks; both groups will be advised to adherence the investigators' diet and exercise program too. At the first and the end of the intervention, metabolic factors will be assessed and compared between groups.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Dietary Supplement: hesperidin Other: control Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Effects of Hesperidin Supplementation in Patients With Metabolic Syndrome
Actual Study Start Date : June 1, 2018
Estimated Primary Completion Date : November 1, 2018
Estimated Study Completion Date : December 1, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: hesperidin Dietary Supplement: hesperidin
500 mg hesperidin as two capsuls

Placebo Comparator: control Other: control
no supplementation




Primary Outcome Measures :
  1. Metabolic syndrome: Number of participants with treated metabolic syndrome [ Time Frame: 12 weeks ]
    number of participants with treated metabolic syndrome



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age of 18 to 70 years
  • having 3 of 5 of high blood sugar, hypertension, high TG, high waist circumference, low HDL

Exclusion Criteria:

  • pregnancy or lactation
  • A history of Cardiovascular disease, Pulmonary disease, Renal disease & Celiac disease; Cirrhosis
  • Following program to lose weight in recent 3 mo

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03734874


Contacts
Layout table for location contacts
Contact: azita Hekmatdoost, MD.PhD +98-21-22077424 a_hekmat2000@yahoo.com

Locations
Layout table for location information
Iran, Islamic Republic of
National Nutrition and Food Technology Research Institute Recruiting
Tehran, Iran, Islamic Republic of
Contact: azita hekmatdoost, MD,PhD         
Sponsors and Collaborators
National Nutrition and Food Technology Institute

Layout table for additonal information
Responsible Party: Dr Azita Hekmatdoost, Principal Investigator, National Nutrition and Food Technology Institute
ClinicalTrials.gov Identifier: NCT03734874     History of Changes
Other Study ID Numbers: 6780
First Posted: November 8, 2018    Key Record Dates
Last Update Posted: November 8, 2018
Last Verified: November 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Metabolic Syndrome
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases